Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 主要终点
- strength measuring 2 acceleromyograph. One Placed at the masseter muscle and the other one at the adductor pollicis muscle.
研究概览
简要总结
The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Scheduled for elective surgery under general anesthesia.
排除标准
- •Pregnancy.
- •Body mass index (BMI) >25 kg/m
- •Anticipated difficult airway.
- •Surgery associated with great volume loss.
- •Presence of any neuromuscular, hepatic, renal, cardiac or respiratory disease.
- •Previous history of neuromuscular blockade allergy, and/or administration of drugs known to interfere with neuromuscular blockade
研究组 & 干预措施
Rocuronium Bromide
Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.
干预措施: Rocuronium Bromide (Drug)
结局指标
主要结局
strength measuring 2 acceleromyograph. One Placed at the masseter muscle and the other one at the adductor pollicis muscle.
时间窗: 60 minutes
Measure blood concentrations after administration rocuronium
时间窗: 120 minutes
次要结局
未报告次要终点
